| Autor: |
Ahmad Faried, MD., PhD, Hendrikus M.B. Bolly, MD., PhD, Yulius Hermanto, MD., PhD, Arifudin Achmad, MD., PhD, Danny Halim, MD., PhD, Firman P. Tjahjono, MD., MSc, Hasrayati Agustina, MD., PhD, Achmad H.S. Kartamihardja, MD., PhD, Muhammad Z. Arifin, MD., PhD |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Interdisciplinary Neurosurgery, Vol 23, Iss , Pp 100939- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2214-7519 |
| DOI: |
10.1016/j.inat.2020.100939 |
| Popis: |
Background: Gliomas are the most prevalent type of primary brain tumors. Clarifying the correlation between glioma markers and disease progression provide a basis for adjuvant treatments. We examined Isocitrate dehydrogenase 1 (IDH1) expression, Ki-67, programmed death-ligand 1 (PD-L1) and L-type amino acid transporter 1 (LAT-1) with respect to overall survival in glioma patients. Methods: Immunohistochemistry (IHC) results from 25 glioma samples were analyzed semi-quantitatively. By WHO criteria, eleven specimens were diagnosed as grade II, 7 as grade III, and 7 as grade IV. Grade II was classified as lower grade glioma (LGG); grade III-IV were classified as high grade glioma (HGG). Results: In this study, immuno-characterization revealed HGG was associated with high Ki-67, PD-L1, and LAT-1 expression (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
